| |
| |
|
| Insider
Information: |
Aryeh Jason |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
401,047 |
|
|
Indirect Shares
|
890,847 |
|
|
| Direct
Value |
$7,198,450 |
|
|
|
Indirect Value
|
$5,034,433 |
|
|
| Total
Shares |
1,291,894 |
|
|
| Total
Value |
$12,232,884 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2024-04-30 |
76,828 |
2024-04-30 |
56,619 |
Premium* |
|
|
Vaxart Inc |
VXRT |
Director |
2010-12-27 |
0 |
2011-03-15 |
131,783 |
Premium* |
|
|
Myrexis Inc |
MYRX |
Director |
|
0 |
2012-06-15 |
552,145 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-05-15 |
242,433 |
2017-05-15 |
150,300 |
Premium* |
|
|
Aralez Pharmaceuticals Inc. |
ARLZ |
Director |
2017-05-23 |
15,000 |
2017-05-23 |
0 |
Premium* |
|
|
Merrimack Pharmaceuticals Inc |
MACK |
See Explanation of Res... |
2019-07-16 |
3,802 |
2019-07-11 |
0 |
Premium* |
|
|
Orchestra BioMed Holdings Inc. |
OBIO |
Director |
2023-04-12 |
62,984 |
2023-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
175 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 6 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2024-04-30 |
4 |
OE |
$52.30 |
$125,834 |
D/D |
2,406 |
76,828 |
0 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2011-12-17 |
4 |
OE |
$5.00 |
$132,500 |
I/I |
25,000 |
486,036 |
0 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2011-11-22 |
4 |
B |
$2.47 |
$132,639 |
I/I |
53,700 |
135,966 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2016-11-16 |
4 |
S |
$106.33 |
$141,419 |
I/I |
(1,330) |
209,377 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2011-03-11 |
4 |
S |
$5.74 |
$142,171 |
I/I |
(24,700) |
140,083 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Director |
– • – |
2017-05-23 |
4 |
S |
$1.41 |
$146,878 |
I/I |
(104,176) |
0 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-06-04 |
4 |
S |
$92.68 |
$151,995 |
I/I |
(1,640) |
244,836 |
0 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2011-11-28 |
4 |
B |
$2.55 |
$165,512 |
I/I |
64,805 |
268,226 |
2.1 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2015-06-30 |
4 |
OE |
$3.27 |
$172,750 |
D/D |
50,000 |
74,000 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-03-22 |
4 |
AS |
$6.24 |
$177,902 |
I/I |
(28,510) |
316,910 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-05-19 |
4 |
S |
$88.82 |
$198,957 |
I/I |
(2,240) |
247,476 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-01-06 |
4 |
AS |
$5.24 |
$222,154 |
I/I |
(42,365) |
737,020 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-09-25 |
4 |
OE |
$6.82 |
$236,584 |
D/D |
20,300 |
53,360 |
0 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2011-11-29 |
4 |
B |
$2.58 |
$236,660 |
I/I |
91,800 |
360,026 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-10-01 |
4 |
OE |
$32.30 |
$236,920 |
D/D |
7,335 |
60,695 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-01-08 |
4 |
AS |
$5.29 |
$244,171 |
I/I |
(46,157) |
687,420 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2017-08-23 |
4 |
S |
$127.99 |
$255,980 |
I/I |
(2,000) |
114,651 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2018-08-16 |
4 |
S |
$245.00 |
$264,600 |
I/I |
(1,080) |
78,254 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2019-07-30 |
4 |
AB |
$100.22 |
$300,663 |
D/D |
3,000 |
64,953 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-11-11 |
4 |
S |
$101.49 |
$304,470 |
I/I |
(3,000) |
241,836 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Director |
– • – |
2017-05-22 |
4 |
S |
$1.42 |
$332,365 |
I/I |
(233,468) |
104,176 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2016-11-25 |
4 |
S |
$106.96 |
$372,007 |
I/I |
(3,478) |
185,898 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-03-23 |
4 |
AS |
$6.25 |
$404,833 |
I/I |
(64,793) |
252,117 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-10-09 |
4 |
B |
$42.99 |
$472,890 |
I/I |
11,000 |
255,716 |
2.1 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-01-12 |
4 |
AS |
$5.49 |
$473,367 |
I/I |
(86,200) |
601,220 |
0 |
- |
|
175 Records found
|
|
Page 6 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
